This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background and Objectives Cancer is a common comorbidity in patients with acute ischemic stroke (AIS). Randomized controlled trials that established endovascular thrombectomy (EVT) as the standard of care for large vessel occlusion generally excluded patients with cancer. As such, the clinical benefits of endovascular thrombectomy in the cancer population are currently poorly established. We examine clinical outcomes of patients with cancer who underwent EVT using a large inpatient database, the National Inpatient Sample (NIS).
Methods The NIS was queried for AIS admission between 2016 and 2019, and patients with cancer were identified. Baseline demographics, comorbidities, reperfusion therapies, and outcomes were compared between patients with AIS with and without cancer. For patients who underwent EVT, propensity score matching was used to study primary outcomes such as risk of intracranial hemorrhage, hospital length of stay, and discharge disposition.
Results During the study period, 2,677,200 patients were hospitalized with AIS, 228,800 (8.5%) of whom had a diagnosis of cancer. A total of 132,210 patients underwent EVT, of which 8,935 (6.8%) had cancer. Over 20% of patients with cancer who underwent EVT had a favorable outcome of a routine discharge home without services. On adjusted propensity score analysis, patients with cancer who underwent EVT had similar rates of intracranial hemorrhage (OR 1.03, CI 0.79–1.33, p = 0.90) and odds of a discharge home, with a significantly higher rate of prolonged hospitalization greater than 10 days (OR 1.34, CI 1.07–1.68, p = 0.01). Compared with patients without cancer, patients with metastatic cancer who underwent EVT also had similar rates of intracranial hemorrhage (OR 1.03, CI 0.64–1.67, p = 1.00) and likelihood of routine discharge (OR 0.83, CI 0.51–1.35, p = 0.54) but higher rates of in-hospital mortality (OR 2.72, CI 1.52–4.90, p < 0.01).
Discussion Our findings show that in contemporary medical practice, patients with acute stroke with comorbid cancer or metastatic cancer who undergo endovascular thrombectomy have similar rates of intracranial hemorrhage and favorable discharges as patients without cancer. This suggests that patients with AIS who meet the criteria for reperfusion therapy may be considered in the setting of a comorbid cancer diagnosis.
Glossary
- AIS=
- acute ischemic stroke;
- EVT=
- endovascular thrombectomy;
- NIS=
- National Inpatient Sample;
- Cancer-AIS=
- cancer–acute ischemic stroke;
- Noncancer-AIS=
- noncancer–acute ischemic stroke;
- Cancer-EVT=
- cancer–endovascular thrombectomy;
- Noncancer-EVT=
- noncancer–endovascular thrombectomy;
- AF=
- atrial fibrillation;
- DM=
- diabetes mellitus;
- HTN=
- hypertension;
- HLD=
- hyperlipidemia;
- CHF=
- chronic heart failure;
- CKD=
- chronic kidney disease;
- NIHSS=
- NIH Stroke Scale;
- DHC=
- decompressive hemicraniectomy;
- PEG=
- percutaneous endoscopic gastrostomy;
- DVT=
- deep venous thrombosis;
- PE=
- pulmonary embolism;
- UTI=
- urinary tract infection;
- MI=
- myocardial infarction;
- AKI=
- acute kidney injury;
- SNF=
- skilled nursing facility;
- CRF=
- chronic renal failure;
- OSA=
- obstructive sleep apnea
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Submitted and externally peer reviewed. The handling editor was José Merino, MD, MPhil, FAAN.
Editorial, page 1021
CME Course: NPub.org/cmelist
- Received February 15, 2022.
- Accepted in final form July 21, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
